These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25773234)

  • 21. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilar insulins are coming: what they are, what you need to know.
    Edelman S; Polonsky WH; Parkin CG
    Curr Med Res Opin; 2014 Nov; 30(11):2217-22. PubMed ID: 25105307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin Pumps.
    Mohnicke M; Blecher A; Beichert K; Bidlingmaier B; Todt EJ; Dette C; Rotthaeuser B; Mukherjee B
    J Pharm Sci; 2023 Apr; 112(4):963-973. PubMed ID: 36521561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biosimilar regulation in the EU.
    Kurki P; Ekman N
    Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins.
    Heinemann L; Khatami H; McKinnon R; Home P
    Diabetes Technol Ther; 2015 Jul; 17(7):510-26. PubMed ID: 25789689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2016 Feb; 18 Suppl 1():S43-55. PubMed ID: 26836429
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography-tandem mass spectrometry.
    Thevis M; Thomas A; Delahaut P; Bosseloir A; Schänzer W
    Anal Chem; 2006 Mar; 78(6):1897-903. PubMed ID: 16536426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilar Insulin and Costs: What Can We Expect?
    Heinemann L
    J Diabetes Sci Technol; 2015 Sep; 10(2):457-62. PubMed ID: 26350722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future.
    Godman B; Haque M; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Allocati E; Bakar MA; Rahim SA; Sultana N; Deeba F; Halim Khan MA; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Acharya J; Sugahara T; Kwon HY; Bae S; Khuan KKP; Khan TA; Hussain S; Saleem Z; Pisana A; Wale J; Jakovljevic M
    Curr Med Res Opin; 2021 Sep; 37(9):1529-1545. PubMed ID: 34166174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.
    Dowlat HA; Kuhlmann MK; Khatami H; Ampudia-Blasco FJ
    Diabetes Obes Metab; 2016 Aug; 18(8):737-46. PubMed ID: 27097592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilar insulins: a European perspective.
    DeVries JH; Gough SC; Kiljanski J; Heinemann L
    Diabetes Obes Metab; 2015 May; 17(5):445-51. PubMed ID: 25376600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of metabolic and mitogenic response in vitro of the rapid-acting insulin lispro product SAR342434, and US- and EU-approved Humalog®.
    Korn M; Wohlfart P; Gossas T; Kullman-Magnusson M; Niederhaus B; Dedio J; Tennagels N
    Regul Toxicol Pharmacol; 2019 Dec; 109():104497. PubMed ID: 31610222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Introduction of biosimilar insulins in Europe.
    Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C
    Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilar insulins are coming: the top 10 things you should know.
    Blumer I; Edelman S
    Postgrad Med; 2014 May; 126(3):107-10. PubMed ID: 24918796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BIOSIMILARS AND NEW INSULIN VERSIONS.
    Peters AL; Pollom RD; Zielonka JS; Carey MA; Edelman SV
    Endocr Pract; 2015 Dec; 21(12):1387-94. PubMed ID: 26340139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical Formulation.
    Gast K; Schüler A; Wolff M; Thalhammer A; Berchtold H; Nagel N; Lenherr G; Hauck G; Seckler R
    Pharm Res; 2017 Nov; 34(11):2270-2286. PubMed ID: 28762200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
    Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
    Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.